刘夏

发布者:王杨发布时间:2021-09-03浏览次数:2170


  刘夏 求是科创学者



        博士,研究浙大科创百人”

        职务:合成生物所 PI

        研究方向:实体瘤免疫治疗、抗肿瘤免疫应答、蛋白质稳态调控

        邮箱:L210136@zju.edu.cn     liuxia1846@gmail.com

        地址:杭州市萧山区建设三路733号浙江大学杭州国际科创中心   




个人简介: 

 刘夏博士,课题组长PI, “浙大科创百人”,浙江大学科创中心青年人才卓越计划入选者。 2009年本科毕业于武汉大学,2014年博士毕业于浙江大学基础医学院免疫所,2014-2016于浙江大学附属第一医院中心实验室担任助理研究员。2016-2020年在Baylor College of Medicine分子生物学系从事博士后科学研究。2021年加入浙江大学杭州国际科创中心生物与分子智造研究院,担任实验室负责人。近年来,在Nat Cell Biol. 、J Clin Invest、Front. Cell Dev. Biol.、eLife,、Cell Death Dis.、Cell Mol Immuno等国际知名期刊发表SCI论文二十余篇,专利两项,主持国家自然科学基金、校企联合项目等多项科研基金,担任多项国际知名期刊的审稿人。刘夏博士长期从事免疫细胞发育与功能调控机制相关性研究,致力于通过基因编辑、智能改造等合成生物学方法技术,研发具有实体瘤特异性杀伤功能的新型细胞治疗方案如CAR-T细胞等。

研究方向:

1.免疫细胞(如HSC,T细胞等)发育与功能的翻译后调控机制;

2.靶向实体瘤的新型细胞免疫治疗策略的开发;

3.通过靶向肿瘤微环境促进免疫治疗响应的新药物研发

发表论文:

  1. Xia liu#; Jingjing Yu#; Longyong Xu#; Katharine Umphred-Wilson#; Fanglue Peng; Yao Ding; Brendan M Barton; Xiangdong Lv; Michael Y Zhao; Shengyi Sun; Yuning Hong; Ling Qi; Stanley Adoro; XiChen; Notch-induced endoplasmic reticulum-associated degradation governs mouse thymocyte β-selection, eLife, 2021, 2021; 10: e69975.(2021; 10: e69975.)  (#Co-first) 

  2. Longyong Xu#; Xia Liu#; Fanglue Peng#; Weijie Zhang#; Liting Zheng; Yao Ding; Tianpeng Gu; Kaosheng Lv; Jin Wang; Laura Ortinau; Tianyuan Hu; Xiangguo Shi; Guojun Shi; Ge Shang; ShengyiSun; Takao Iwawaki; Yewei Ji; Wei Li; Jeffrey M. Rosen; Xiang H.-F. Zhang; Dongsu Park; Stanley Adoro; Andre Catic; Wei Tong; Ling Qi; Daisuke Nakada; Xi Chen; Protein quality control through endoplasmic reticulum-associated degradation maintains hematopoietic stem cell identity and niche interactions, Nat Cell Biol, 2020, 22(10): 1162-1169 (#Co-first)

  3. LiuX,YinS,CaoW,FanW,YuL,YinL,WangL,WangJ.Runt-relatedtranscription factor 3 is involved in the altered phenotype and function in ThPok-deficient invariant natural killer T cells. Cell Mol Immunol. 2014 May; 11(3):232-44. doi: 10.1038/cmi.2014.3.

  4. Xuefen Li#; Xia liu#; Weilin Wang; IL-35: A Novel Immunomodulator in Hepatitis B Virus-Related Liver Diseases, Front. Cell Dev. Biol., 2021, 9(614847)

  5. YeB,LiuX,LiX,KongH,TianL,ChenY.Tcellexhaustioninchronichepatitis B infection: current knowledge and clinical significance. Cell Death Dis. 2015 Mar 19;6:e1694. doi: 10.1038/cddis.2015.42.

  6. LiX,LiuX,TianL,ChenY.Cytokine-MediatedImmunopathogenesisofHepatitis B Virus Infections. Clin Rev Allergy Immunol.2016 Feb; 50(1):41-54.doi: 10.1007/s 12016-014-8465-4.5.

  7. Li X, Tian L, Dong Y, Zhu Q, Wang Y, Han W, Liu X, Ni Q, Chen Y, Li L.IL-35 inhibits HBV antigen-specific IFN-γ-producing CTLs in vitro. Clin Sci (Lond). 2015 Sep; 129(5):395-404. doi: 10.1042/CS20140511.

  8. LiM,CaoW,LiuH,ZhangW,LiuX,CaiZ,GuoJ,WangX,HuiZ,ZhangH,Wang J, Wang L. MCPIP1 down-regulates IL-2 expression throughan ARE-independent pathway. PLoS  One.  2012;7(11):e49841.  doi:  10.1371  /  journal.  Pone.  0049841.

  9. Shengxia,Yin, Jingjing, Yu, Bian, Hu,Chenyu, Xia Liu, Xianzhi Gao,Wei Li,Lina Zhou, Jianli Wang, Diang, Linrong Lu and Lie Wang Runx3 mediates resistance to intracellular bacterial infection by promoting IL12 signaling in Group1 ILC and NCR+ILC3.Front.Immunol.2018.Feb;doi:10.3389/fimmu.(IF=6.429)

  10. Na Zhao, Jin Cao, Longyong Xu, …Xia Liu, Wen Bu, Michael T. Lewis, and Xi Chen Pharmacological targeting of MYC-regulated IRE1/XBP1 pathway suppresses MYC-driven breast cancer. J Clin Invest. 2018 Apr 2;128(4):1283-1299.

  11. Koh EH2, Chernis N, Saha PK, Xiao L Bader DA, Zhu B, Rajapakshe K,Hamilton MP1, Liu X, Perera D, Chen X, York B, Trauner M, Coarfa C, Bajaj M, Moore DD, Deng T, McGuire SE, Hartig SM.miR-30a Remodels Subcutaneous Adipose Tissue Inflammation to Improve Insulin Sensitivity in Obesity. Diabetes. 018 Jul 12. pii: db171378. doi: 10.2337/db17-1378. (IF=7.273)

  12. Zhaoyuan Hui, Lina Zhou, Zhonghui Xue, Lingfeng Zhou, Yikai Luo, Feng Lin, Xia Liu, Shenghui Hong, Wei Li, Di Wang, Linrong Lu, Jianli Wang, and Lie Wang.Cxxc Finger Protein 1 Positively Regulates GM-CSF-Derived Macrophage Phagocytosis Through Csf2rα-Mediated Signaling. Front Immunol, 2018. 9: p. 1885.

  13. Han W, Ni Q, Liu  K,  Yao  Y,  Zhao  D,  Liu X,  Chen  Y. DecreasedCD122onCD56dimNKassociatedwithitsimpairmentinasymptomatic chronic HBV carriers with high levels of HBV DNA, HBsAg and HBeAg..  Life  Sci.  2018  Feb  15;195:53-60.

  14. 11.ZhaoD,HanW,LiuX,CuiD,ChenY.MicroRNA-128promotesapoptosisinlung cancerbydirectlytargetingNIMA-relatedkinase2.ThoracCancer.2017Jul;8(4):304-311.

  15. Bo Ye, Xuefen Li, Yuejiao Dong, Yiyin Wang, Li Tian Sha Lin, Xia Liu, Haishen Kong, and Yu Chen.



承担基金:

1.国家自然科学基金委员会,面上项目,81971919IP-10通过调控ICAM-1表达在流感病毒致细菌共感染中的分子机制研究,2020-01-012023-12-3155万元,在研,参与

2.国家自然科学基金委员会,青年科学基金项目,81802887lncRNA-FAM83A-AS1/STAT3/SOX5信号轴在调控肺腺癌转移及肿瘤干性维持的作用机制研究,2019-01-012021-12-3121万元,在研,参与

3.国家自然科学基金委员会,面上项目,81672092iTR35诱导HBV特异性CTL耗竭的分子机制及其靶向干预研究,2017-01-012020-12-3158万元,结题,参与

4.国家自然科学基金委员会,面上项目,81672014Galectin-1在人感染H7N9禽流感致急性肺损伤中的作用机制研究,2017-01-012020-12-3157万元,结题,参与

5.国家自然科学基金委员会,青年项目,81500434“ThPok 调控 NKT 细胞在自身免疫性肝炎中的作用探讨青年项目,01/01/2016-12/31/2018 结题,主持

发明专利:

1.一种T细胞向肿瘤迁移的负调控因子的体外筛选、鉴定方法

2.一种人原代CAR-T细胞体外耗竭模型的建立